UK pharma has concerns about the new NHS 10-year plan
The ABPI is worried about investment in medicines and moves that could limit patient and doctor treatment choice in the NHS 10-year plan.
AZ claims EU okay for Imfinzi in bladder cancer
AstraZeneca passes another milestone in its journey to rebuild Imfinzi's presence in bladder cancer, a key growth driver for the drug.
Pharma welcomes EU push to restore life sciences sector
European pharma trade group EFPIA has said that a strategy launched by the EU to bolster the region's standing in life sciences is a "step forward."
Summit climbs on rumour of $15bn AstraZeneca interest
Is AstraZeneca about to join the ranks of pharma companies spending big bucks on PD(L)-1xVEGF bispecific antibodies for cancer?
NICE relents on Takeda colorectal cancer drug Fruzaqla
Colorectal cancer patients could soon have access via the NHS to a targeted oral drug that can give them more precious time with their loved ones.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The World's Definitive Degrader & Proximity-Based Drugs Even...
The 8th Annual TPD & Induced Proximity Summit is the world’s largest and longest-standing forum for proximity-based modalities
Welcome to the 7th Exosome-Based Therapeutic Development Sum...
Accelerate Therapeutic Efficacy & Delivery Potential of Exosomes & EVs
Welcome to the 10th CDD for Biologics Summit
Accelerate Therapeutic Efficacy & Delivery Potential of Exosomes & EVs
The Inaugural Multi-Omics Based Drug Discovery & Development
The Industry-Led Forum Dedicated to Expanding the Applications of Multi-Omics Across Therapeutic Development
2nd Translational Digital Pathology & AI Summit
Don’t miss the return of this event, uniting 60+ leading biopharma pioneers driving the adoption and utilization of digital pathology